Latest Evista Stories
INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ -- -- Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S.
INDIANAPOLIS, July 24, 2014 /PRNewswire/ -- -- Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S.
-- First-quarter 2014 revenue declined 16 percent driven by the impact of U.S.
- Prasco to market the Authorized Generic of EVISTA® in the United States CINCINNATI, April 1, 2014 /PRNewswire/ -- Prasco
INDIANAPOLIS, Aug. 9, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data on EVISTAÂ® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.
BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore.
Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects.
MUNICH, June 28, 2010 /PRNewswire/ -- - 3D Images Provide New Approach to Monitoring Bone Changes Interim data from a prospective Investigator Initiated Trial (IIT) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA(R) (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the...
MORRISTOWN, N.J., May 5 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S.
INDIANAPOLIS, Sept. 23 /PRNewswire-FirstCall/ -- The U.S. District Court for the Southern District of Indiana today upheld Eli Lilly and Company's (NYSE: LLY) method-of-use patents on Evista(R) (raloxifene HCl tablets). In the case of Eli Lilly and Company v.
- A transitional zone between two communities containing the characteristic species of each.